Immunic OverviewImmunic EBIT
EBIT (Earnings Before Interest and Taxes) analysis for IMUX.
Quarterly EBIT
-$33.24M
↓ 23.9% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$104.93M
↓ 3.87% YoY
Trailing 12 months ending Mar 31, 2026
Immunic OverviewEBIT (Earnings Before Interest and Taxes) analysis for IMUX.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026